阿加曲班联合尤瑞克林治疗急性脑梗死效果的meta分析

doi:10.20047/j.issn1673-7210.2023.11.16

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (3230 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically review the efficacy and safety of Argatroban combination with Urinary Kallidinogenase in the treatment of acute cerebral infarction. Methods SinoMed, CNKI, Wanfang Data, VIP, PubMed, Cochrane Library, Embase, and Web of Science were searched by computer from the inception to March 2022. Randomized controlled trials of Argatroban combined with Urinary Kallidinogenase for acute cerebral infarction were screened, data extraction and systematic review were conducted, and meta-analysis was performed by RevMan 5.4 software. Results Eight studies were included, involving 789 subjects. Meta-analysis showed that the effective rate (RR=1.22, 95%CI: 1.14 to 1.30, P＜0.000 01) and Barthel index (MD=9.77, 95%CI: 7.27 to 12.28, P＜0.05) in the Argatroban combined with Urinary Kallidinogenase group were higher than those in the control group, National Institute of Health stroke scale scores were lower than those in the Argatroban control group (MD=-3.30, 95%CI: -3.87 to -2.74, P＜0.000 01) and the Urinary Kallidinogenase control group (MD=-1.79, 95%CI: -2.16 to -1.42, P＜0.000 01). Conclusion Argatroban combined with Urinary Kallidinogenase is effective in the treatment of acute cerebral infarction, which could effectively improve the degree of neurological deficits and the activities of daily living.

Key words： Argatroban Urinary Kallidinogenase Acute cerebral infarction Meta-analysis Randomized controlled trial

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qingli LI Zhe MA Zhongliang LIAN Shuai XUE Mengzhou

Cite this article:

WANG Qingli LI Zhe MA Zhongliang LIAN Shuai XUE Mengzhou. Meta-analysis of the efficacy and safety of Argatroban combined with Urinary Kallidinogenase in the treatment of acute cerebral infarction[J]. 中国医药导报, 2023, 20(11): 71-74.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.11.16 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I11/71

[1] Takeda H，Yamaguchi T，Yano H，et al. Microglial metabolic disturbances and neuroinflammation in cerebral infarction [J]. J Pharmacol Sci，2021，145（1）：130-139.
[2] Huang P，He X，Xu M. Effect of argatroban injection on clinical efficacy in patients with acute cerebral infarction：preliminary findings [J]. Eur Neurol，2021，84（1）：38-42.
[3] Zhao Y，Zhang X，Chen X，et al. Neuronal injuries in cerebral infarction and ischemic stroke：From mechanisms to treatment（Review）[J]. Int J Mol Med，2022，49（2）：15.
[4] 曹杰，张培，刘晨辰.阿加曲班联合依达拉奉治疗急性脑梗死疗效的Meta分析[J].微循环学杂志，2018，28（3）：51- 57.
[5] Jin Y，Mima T，Raicu V，et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils [J]. Neurosci Res，2002，43（1）：75-79.
[6] Moledina M，Chakir M，Gandhi PJ. A synopsis of the clinical uses of argatroban [J]. J Thromb Thrombolysis，2001，12（2）：141-149.
[7] Zou W，Deng Y，Chen G，et al. Influence of butyphthalide combined with urinary kallikrein in ACI treatment on neuro-cytokines and vascular endothelial function and its clinical effect [J]. Int J Neurosci，2021，131（1）：25-30.
[8] 中华神经学会，中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志，1996（6）：60-61.
[9] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015（4）：246-257.
[10] 全国第四届脑血管病学术会议.脑卒中患者临床神经功能缺损程度评分标准（1995）[J].中华神经科杂志，1996（6）：62-64.
[11] 司君增，郭秀玲，亓勤德.阿加曲班联合尤瑞克林治疗进展性脑梗死疗效对比研究[J].中国医学装备，2016， 13（1）：108-111.
[12] 徐斌，赵海玲，张勇，等.不同药物治疗进展性脑梗死观察鏯[J].海南医学院学报，2013，19（2）：191-193.
[13] 王桢，陈秀菊.尤瑞克林联合阿加曲班治疗急性脑梗死临床观察[J].中国城乡企业卫生，2016，31（1）：94-96.
[14] 王洁，涂明轩.尤瑞克林联合阿加曲班治疗急性脑梗死的临床效果[J].实用临床医学，2018，19（5）：22-23.
[15] 王胜英，李高华，满彦杰.阿加曲班联合尤瑞克林治疗进展性脑梗死患者临床观察[J].中医临床研究，2017，9（27）：42-44.
[16] 王茜，周辰珩.强化药物方案对急性分水岭脑梗死患者凝血功能指标及预后的影响[J].中国医刊，2021，56（8）：916-919.
[17] 薛艳立.探讨尤瑞克林联合阿加曲班治疗急性脑梗死有效性及安全性[J].临床军医杂志，2016，44（4）：434- 436.
[18] 赵新侠.尤瑞克林联用阿加曲班治疗急性脑梗死临床研究[J].北方药学，2017，14（2）：66-67.
[19] Wen H，Lv M. Correlation analysis between serum procalcitonin and infarct volume in young patients with acute cerebral infarction [J]. Neurol Sci，2021，42（8）：3189-3196.
[20] Li X，Bu S，Pan RR，et al. The values of AHCY and CBS promoter methylation on the diagnosis of cerebral infarction in Chinese Han population[J]. BMC Medical Genomics，2020，13（1）：163.
[21] Morris DC，Zhang LI，Zhang ZG，et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke [J]. Stroke，2001，32（11）：2635-2640.
[22] Chen JL. Argatroban：a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications [J]. Heart Dis，2001，3（3）：189-198.
[23] Imiya M，Matsuo T. Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction [J]. Thromb Res，1997，88（2）：245-250.
[24] Ishibashi H，Koide M，Obara S，et al. High-dose argatroban therapy for stroke：novel treatment for delayed treatment and the recanalization mechanism [J]. J Stroke Cerebrovasc Dis，2013，22（5）：656-660.
[25] Wang Y，Chen Y，Zhang C，et al. Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction [J]. Eur Rev Med Pharmacol Sci，2015， 19（6）：1009-1012.
[26] Fan Q，Qiu Z，Zhang X. Influences of urinary kallidinogenase on neuronal apoptosis in cerebral infarction rats through Nrf2/ARE oxidative stress pathway [J]. Eur Rev Med Pharmacol Sci，2019，23（15）：6665-6671.